Form 4: Axsome Therapeutics CFO Nick Pizzie Reports Stock Option and Restricted Stock Unit Grants

Axsome Therapeutics' CFO, Nick Pizzie, reported the acquisition of stock options and restricted stock units (RSUs) in a recent SEC filing.

Summary

• On February 27, 2024, Nick Pizzie, the Chief Financial Officer of Axsome Therapeutics, Inc., was granted employee stock options to purchase 28,722 shares of common stock.
• These options have an exercise price of $84 and will vest in equal quarterly installments over four years, becoming fully vested on February 27, 2028.
• Pizzie also received 15,774 restricted stock units (RSUs) on the same date.
• 25% of the RSUs will vest on the one-year anniversary of the grant date, with the remaining RSUs vesting in three equal annual installments, fully vesting on February 27, 2028.
• Vested shares from the RSUs will be delivered upon a change in control, separation of service, or seven years from the grant date.

Sentiment

Score: 7

Explanation: The document reflects a neutral to slightly positive sentiment as it reports standard executive compensation practices, indicating confidence in the company's future.

Positives

• The grant of stock options and RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Stock option and RSU grants are common compensation practices in the pharmaceutical industry to attract and retain key executives and align their interests with shareholder value.

Comparison to Industry Standards

• Stock option and RSU grants are a standard component of executive compensation packages in the pharmaceutical industry.
• Companies like Biogen, Amgen, and Gilead Sciences also utilize similar equity-based compensation plans to incentivize their executives.
• The vesting schedules and terms of these grants are generally comparable to industry norms, designed to promote long-term commitment and performance.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning management's interests with the company's long-term performance.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates